Phase II study of CDDP/Alimuta combined with bevacizumab in patients with advanced non-small-cell lung cancer without harboring sensitive EGFR mutations.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 May 2016
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALPS
- 20 May 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2011 New trial record